NEW YORK–(BUSINESS WIRE)–Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) (“Rocket”), a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare disorders, today announces the appointment of Elisabeth Bjӧrk, M.D., Ph.D. to its Board of Directors.
“I am honored that Elisabeth will be joining Rocket’s Board of Directors,” said Gaurav Shah, M.D., Chief Executive Officer and President at Rocket. “Elisabeth’s appointment coincides with a period of accelerated clinical trial progress at Rocket. The depth of her experience in complex life-threatening disorders and her drug development expertise—from discovery through launch—comes at a perfect time in Rocket’s journey. We are particularly excited as her presence will augment our existing Board of Directors’ world-class research and financial expertise. Collectively, the management team could not hope for a better group of advisors and stewards for Rocket Pharma.”
Dr. Bjӧrk is the Senior Vice President, Head of Late-stage Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D at AstraZeneca leading the global development of medicines within this area. Throughout her career at AstraZeneca, she has gained broad drug development experience covering clinical development phase I-IV, large outcomes programs, major global filings and health authority interactions (FDA, EMA, Japan) and commercial strategy/implementation. Dr Bjӧrk is an endocrinologist by training and an associate professor of medicine at Uppsala University, Sweden. She is also a board member of Chalmers University of Technology, Chalmers Ventures AB, Bjӧrks Matematik o Mera AB and rfidcompare europe AB.
“I am delighted to join Rocket’s Board of Directors,” said Dr. Bjӧrk. “With strong leaders in place, Rocket is relentlessly focused on serving patients with devastating and rare diseases. Their dedicated and talented team, coupled with compelling AAV and Lentiviral platforms, creates a bright future for Rocket, and strong potential to develop and deliver life-transforming therapies for patients who need them.”